Association between serum gamma-glutamyltransferase and early-onset coronary artery disease: a retrospective case-control study

• Published in: Annals of medicine (Helsinki) Vol. 55; no. 2; p. 2289606
• Main Authors: Xuan, Chao, Li, Jing, Liu, Ru-Hua, Guo, Jun-Jie, Zhao, Cong, Zhou, Ting-Ting, Wang, Yan, He, Guo-Wei, Lun, Li-Min
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis Group 2023
• Subjects: Atherosclerosis; Biomarkers; cardiovascular disease; Case-Control Studies; Coronary Artery Disease; early-onset; Gamma-glutamyltransferase; Humans; Retrospective Studies; Risk Factors; coronary artery disease; cardiovascular disease; Gamma-glutamyltransferase; early-onset
• ISSN: 0785-3890; 1365-2060
• DOI: 10.1080/07853890.2023.2289606

Serum gamma-glutamyltransferase (GGT) activity has been proposed as a promising predictor of atherosclerosis-related complications and a prognostic marker for cardiovascular diseases. The objective of this study was to investigate the potential correlation between serum levels of GGT and early-onset coronary artery disease (EOCAD). A retrospective, hospital-based case-control study was conducted, which included 860 patients with EOCAD and gender- and age-matched controls. Serum levels of GGT were measured using the reference measurement procedure on an automatic biochemistry analyser. The serum GGT levels of patients with EOCAD (34.90 ± 31.44 U/L) were significantly higher than those of the control group (21.57 ± 16.44 U/L,  < .001). Elevated serum levels of GGT were found to be an independent risk factor for EOCAD, with an odds ratio (OR) of 1.021 (95% confidence interval (CI): 1.014-1.029). Additionally, for every quartile increase in serum GGT levels, the risk of developing EOCAD increased by 1.6-fold. Moreover, serum GGT levels were significantly associated with disease severity, with lower GGT levels observed in patients without significant vascular disease (31.74 ± 24.06 U/L) compared to those with two-vessel disease (33.06 ± 25.00 U/L,  = .002) and three-vessel disease (37.75 ± 36.76 U/L,  = .001). The results of this study suggest that elevated serum GGT levels are associated with the development of EOCAD, and GGT may be implicated in the pathogenesis of the disease. Further large-scale prospective studies are needed to explore the potential relationship between serum GGT levels and the dynamic development of EOCAD.